Outsourcing in Clinical Trials Southeast 2014March 4-5, 2014, Cary, NC
North Carolina: the epicenter of the biotech and CRO industries...
Outsourcing in Clinical Trials Southeast has become the leading roadshow for the pharmaceutical, biotech and medical device industries in North Carolina and the Southeast United States.
Now in its 3rd exciting year, OCT Southeast will take an in-depth look at the challenges and opportunities facing small to medium drug developers and their clinical partners.
Learn about the essential tools for effective vendor selection and partnership optimization that every clinical professional should have in their arsenal. Hear how to achieve excellence in data management and clinical study informatics. Plus: expert advice on funding and investment, as well as the latest in patient recruitment and trial monitoring.
Benefit from an unrivalled line up of speakers, including 11 small/medium and biotech, 8 c-level presenters, leading academics, investors and clinical experts
The 3rd Annual Outsourcing in Clinical Trials Southeast is an essential platform for biotech, pharma and medical device professionals from North Carolina and surrounding states, to discuss specific challenges, identify key opportunities and network with peers and partners in the Southeast region.
OCT Southeast is designed in collaboration with local industry experts, who play a key role in ensuring the agenda content is exactly what clinical outsourcing professionals like you need in order to maximise the value of your conference experiences.
The beauty of this unique event is its truly local reach, and roster of specifically tailored topics, expert speakers and fruitful networking sessions. OCT Southeast 2014 will help you achieve optimal results from your clinical outsourcing programs.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
Outsourcing in Clinical Trials Southeast boasts a fantastic exhibition of outsourcing service providers and industry specialists. Our exhibition area is already filling up due to the fantastic event which took place in May 2013.
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
With focused sessions, interactive panel discussions and peer-to-peer networking, this event will offer delegates a forum in which to learn more about the challenges, innovations and opportunities impacting clinical outsourcing in the RPT area, as well as how local CROs and service providers can deliver customised solutions.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout The Research Triangle Park.
US-based biopharmaceutical firm Portola Pharmaceuticals has released additional results of a Phase II proof-of-concept trial of its investigational Factor Xa inhibitor antidote 'andexanet alfa (PRT4445)', in healthy volunteers who were administered t…
US-based biotechnology firm Gilead Sciences has released interim results of a single-arm, open-label Phase II study of its investigational oral inhibitor of spleen tyrosine kinase (Syk) GS-9973 for treatment of patients with relapsed or refractory ha…
US-based clinical stage biotechnology firm Catabasis Pharmaceuticals has started the second Phase II clinical trial to assess the safety and efficacy of CAT-2003 in patients with severe hypertriglyceridemia, defined as serum triglyceride levels of 50…
GlaxoSmithKline (GSK) and Theravance have released positive results from a Phase III efficacy and safety trial of fluticasone furoate(FF)/vilanterol (VI) designed to support a potential filing for an asthma indication for adults in the US.
OncoMed Pharmaceuticals has initiated a Phase Ib clinical trial of its Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer.